OpGen Inc. (OPGN) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
9717 KEY WEST AVENUE ROCKVILLE, MD 20850 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 8071 - Medical Laboratories (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1,311 | 1,152 | 7,440 | 36,080 | 13,360 | 2,708 | |||
| Cash and cash equivalent | 1,311 | 1,152 | 7,440 | 36,080 | 13,360 | 2,708 | |||
| Receivables | 29 | 103 | 514 | 1,172 | 653 | 3,089 | |||
| Inventory, net of allowances, customer advances and progress billings | 1,226 | (1,281) | 3,646 | 4,712 | 1,486 | 473 | |||
| Inventory | 1,226 | (1,281) | 3,646 | 4,712 | 1,486 | 473 | |||
| Other undisclosed current assets | 83 | 1,606 | (945) | (2,222) | 1,388 | 397 | |||
| Total current assets: | 2,649 | 1,580 | 10,655 | 39,743 | 16,888 | 6,667 | |||
| Noncurrent Assets | |||||||||
| Inventory, Noncurrent | 2,301 | 3,472 | 1,686 | ||||||
| Finance lease, right-of-use asset, after accumulated amortization | 0 | 4 | 90 | 450 | 959 | ||||
| Operating lease, right-of-use asset | 826 | 1,459 | 1,814 | 2,082 | 1,044 | ||||
| Property, plant and equipment | 1,079 | 3,458 | 4,012 | 3,259 | 131 | ||||
| Intangible assets, net (including goodwill) | 7,441 | 21,983 | 24,606 | 1,418 | |||||
| Goodwill | 7,453 | 8,025 | 601 | ||||||
| Intangible assets, net (excluding goodwill) | 7,441 | 14,530 | 16,581 | 818 | |||||
| Other noncurrent assets | 302 | 302 | 496 | 552 | 780 | 203 | |||
| Other undisclosed noncurrent assets | 5,006 | ||||||||
| Total noncurrent assets: | 7,213 | 302 | 15,158 | 31,924 | 32,863 | 3,755 | |||
| TOTAL ASSETS: | 9,863 | 1,882 | 25,813 | 71,667 | 49,751 | 10,422 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 307 | 247 | 1,947 | 4,895 | 5,432 | 2,959 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 1,622 | 2,127 | 856 | ||
| Accounts payable | 245 | 111 | 421 | 1,307 | 1,869 | 1,056 | |||
| Accrued liabilities | 62 | 135 | 1,526 | 1,966 | 1,437 | 1,047 | |||
| Deferred revenue | 26 | 142 | 10 | 10 | |||||
| Debt | 10,874 | 7,027 | 14,562 | 1,664 | 1,970 | ||||
| Other undisclosed current liabilities | 327 | 276 | 1,475 | 460 | 265 | ||||
| Total current liabilities: | 634 | 11,422 | 10,592 | 19,917 | 7,372 | 4,939 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 4,851 | 10,157 | 20,918 | 1,190 | |||||
| Long-term debt, excluding current maturities | 4,851 | 7,176 | 19,379 | 329 | |||||
| Finance lease, liability | 0 | 4 | 47 | 313 | |||||
| Liabilities, other than long-term debt | 1,848 | 2,022 | 2,795 | 375 | 269 | ||||
| Other liabilities | 129 | 147 | 157 | ||||||
| Operating lease, liability | 1,848 | 2,022 | 2,566 | 2,977 | 1,493 | 547 | |||
| Derivative instruments and hedges, liabilities | 99 | 229 | 113 | ||||||
| Total noncurrent liabilities: | 1,848 | 2,022 | 7,646 | 10,533 | 21,188 | 1,190 | |||
| Total liabilities: | 2,482 | 13,444 | 18,238 | 30,449 | 28,560 | 6,128 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 7,381 | (11,562) | 7,576 | 41,217 | 21,191 | 4,293 | |||
| Preferred stock | 3 | ||||||||
| Common stock | 101 | 13 | 29 | 465 | 251 | 56 | |||
| Additional paid in capital | 300,780 | 293,992 | 281,167 | 275,708 | 219,129 | 178,780 | |||
| Accumulated other comprehensive income (loss) | (75) | (796) | 586 | 2,547 | (17) | ||||
| Accumulated deficit | (293,501) | (305,493) | (272,825) | (235,542) | (200,736) | (174,525) | |||
| Other undisclosed equity, attributable to parent | 0 | ||||||||
| Total equity: | 7,381 | (11,562) | 7,576 | 41,217 | 21,191 | 4,293 | |||
| TOTAL LIABILITIES AND EQUITY: | 9,863 | 1,882 | 25,813 | 71,667 | 49,751 | 10,422 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 5,196 | 3,418 | 2,607 | 4,306 | 4,214 | 3,499 | ||
| Cost of revenue | (107) | (14,919) | (3,320) | (2,848) | (1,015) | (2,120) | ||
| Cost of product and service sold | (3,084) | (3,320) | ||||||
| Gross profit: | 5,089 | (11,501) | (712) | 1,458 | 3,199 | 1,379 | ||
| Operating expenses | (4,765) | (19,248) | (33,855) | (24,731) | (25,918) | (13,650) | ||
| Operating income (loss): | 325 | (30,749) | (34,567) | (23,273) | (22,718) | (12,271) | ||
| Nonoperating income (expense) | 11,845 | (1,920) | (2,716) | (11,489) | (3,360) | (175) | ||
| Gain (loss), foreign currency transaction, before tax | 1 | (289) | 380 | 891 | (1,469) | 2 | ||
| Interest and debt expense | (8) | (1,839) | (3,256) | 259 | 885 | (188) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | 12,162 | (34,507) | (40,540) | (34,503) | (25,193) | (12,634) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 8 | 1,839 | 3,256 | (259) | (885) | 188 | ||
| Income (loss) from continuing operations before income taxes: | 12,169 | (32,669) | (37,283) | (34,762) | (26,078) | (12,446) | ||
| Income tax expense | (177) | (44) | (132) | |||||
| Other undisclosed loss from continuing operations | ||||||||
| Income (loss) from continuing operations: | 11,993 | (32,669) | (37,283) | (34,806) | (26,211) | (12,446) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (34,806) | (26,211) | (12,446) | |
| Net income (loss) attributable to parent: | 11,993 | (32,669) | (37,283) | (34,806) | (26,211) | (12,446) | ||
| Preferred stock dividends and other adjustments | (7,167) | |||||||
| Other undisclosed net loss available to common stockholders, basic | (637) | |||||||
| Net income (loss) available to common stockholders, basic: | 11,356 | (32,669) | (37,283) | (41,972) | (26,211) | (12,446) | ||
| Dilutive securities, effect on basic earnings per share | 565 | |||||||
| Other undisclosed net income available to common stockholders, diluted | 72 | |||||||
| Net income (loss) available to common stockholders, diluted: | 11,993 | (32,669) | (37,283) | (41,972) | (26,211) | (12,446) | ||
Comprehensive Income ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 11,993 | (32,669) | (37,283) | (34,806) | (26,211) | (12,446) | ||
| Comprehensive income (loss): | 11,993 | (32,669) | (37,283) | (34,806) | (26,211) | (12,446) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 721 | (1,381) | (1,962) | 2,564 | (4) | |||
| Comprehensive income (loss), net of tax, attributable to parent: | 11,993 | (31,948) | (38,665) | (36,767) | (23,646) | (12,451) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.